Anupco


BUPARVAX

Solution for injection

COMPOSITION

Buparvaquone 50 mg

Excipients up to 1 ml.

PHARMACOLOGICAL PROPERTIES

Buparvaquone is an hydroxynaphtoquinone active against the schizont and piroplasm stages of Theileria spp. It can be used for treatment of clinically sick animals but also for prevention during incubation in all in-contact animals before showing clinincal signs. The mode of action of buparvaquone on Theileria is not yet established, althought there are indications of an effect on energy generation.

INDICATIONS

Indicated for the treatment of theileriosis (East Coast Fever, Corridor Disease) in cattle caused by Theileria parva parva, Theileria parva bovis, Theileria parva lawrencei, Theileria annulata, Theileria mutans and Theileria orientalis sergenti.

CONTRA-INDICATIONS

Intravenous or subcutaneous injections are contra-indicated.

Avoid I.M. administration in horses.

DOSAGE AND MODE OF ADMINISTRATION

2.5 mg/ kg bodyweight or 1 ml BUPARVAX per 20 kg body weight by intramuscular injection. In severe cases a second identical dose may be injected 48-72 hours after the first injection. If more than 10 ml is to injected, the total volume should be divided over two injection sites, one on each side of the neck.

UNDESIRABLE EFFECTS

Transient painless local swellings at the injection site may occasionally occur.

SPECIAL PRECAUTIONS FOR USE AND WARNINGS

Normal asceptic precautions should be taken.

PACK SIZE

50 ml vials.

Please be aware that product specifications and availability can differ between countries. For detailed information in this regard, please contact us.

You are viewing the English version of this website enesfr